Drozitumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Drozitumab
Monoclonal antibody
Type Whole antibody
Source Human
Target DR5
Identifiers
CAS Number 912628-39-8 N
ATC code none
ChemSpider none
UNII SQ67484MA7 YesY
Chemical data
Formula C6334H9792N1700O2000S42
Molar mass 143.1 kg/mol
 NYesY (what is this?)  (verify)

Drozitumab is a human monoclonal antibody designed for the treatment of cancers.[1]

Drozitumab was developed by Genentech.

Adverse drug effects[edit]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.